Stifel’s European Healthcare Team provides capital markets and advisory services on a pan-European and global basis across the full range of healthcare companies, from biotech, medtech, and diagnostics to animal health, OTC, and specialty pharma as well as outsourced pharma services and healthcare services.
We provide a full-service product offering to clients including M&A (both company and asset based), equity capital raising (including both IPOs and follow-on offerings), corporate broking services for listed companies, and capital solutions. We have particular expertise in helping European biotechnology companies access the U.S. capital markets. We have served as bookrunner on three of the UK/European healthcare company dual listings on Nasdaq in 2020 year to date and are a leading global franchise in branded healthcare products, such as animal health and OTC/consumer health.
The team’s success has been built on its deep industry and scientific knowledge, exceptional access to investors, and global connectivity in our core segments, which allows our team to offer a comprehensive and integrated approach to addressing clients’ needs in the most effective way. We also work closely with our U.S. banking partners, offering a highly differentiated proposition for UK and European companies raising capital in the U.S.
Dollar volume represents full credit to each underwriter. All transaction announcements appear as a matter of record only. Stifel collectively refers to Stifel, Nicolaus & Company, Incorporated and other affiliated broker-dealer subsidiaries of Stifel Financial Corp. Unless otherwise indicated, information presented herein with respect to the experience of Stifel also includes transactions effected and matters conducted by companies acquired by Stifel (including pending acquisitions publicly announced by Stifel).
Healthcare Transactions Announced Globally Since March 2020
in Equity Deals Under $1 Billion Market Cap
Source: Dealogic. Rank-eligible SEC registered IPOs and follow-on offerings since 2010 as of 31/01/20
Among Middle-Market Firms in M&A Transactions Under $1 Billion
Source: M&A Analytics as of 31/01/20
in All Managed Venture Capital-Backed IPOs
Source: Dealogic. Venture-backed IPOs ranking since 2005 as of 31/12/19. (8) M&A Analytics as of 31/01/20